Currently, Yikon Genomics includes Shanghai Xukang Medical Technology Co., Ltd., Shanghai Yikon Medical Laboratory Co., Ltd., Suzhou Yikon Medical Laboratory Co., Ltd. and Xukang Medical Technology (Suzhou) Co., Ltd and two offices located in Guangzhou and Wuhan.
As a Knowledge-Intensive Enterprise in the precision medicine industry, Yikon Genomics has established a high-level technical and management team, of which 78% have a bachelor's degree or above, 34% have a master's degree or above, and 8% have a doctoral degree. The talents from Harvard University, Vanderbilt University, University of California, Berkeley, and University of Guelph in Canada, returned to China and are responsible for technology. Moreover, academicians of the American Academy of Sciences and domestic science leaders served as consultants to the scientific committee; at the same time, Yikon Genomics strictly controlled the quality of products and testing services, which have passed ISO9001:2015 and ISO13485: 2016 International Quality Certification. Yikon Medical Laboratory obtained the "The Practice License of Medical Institution" approved by the Shanghai Municipal Health Commission, which permits to provide domestic and foreign medical institutions, scientific research institutes, groups and individuals with Nearly a hundred testing services in fields of reproductive genetics, maternal and child health, tumor screening and life science research. In June 2017, Yikon Genomics PGS Kit passed the special approval of CFDA for innovative medical devices.
At present, Yikon Genomics has provided kits and medical testing services to more than 100 large domestic medical institutions, including the Third Hospital of Peking University, the General Hospital of the People's Liberation Army (301 Hospital), and the First Affiliated Hospital of Zhengzhou University, as well as world-class scientific research institutes. The preimplantation embryo genetic screening/diagnosis (PGS/PGD) service of Yikon Genomics can detect more than one hundred chromosomal genetic diseases and single-gene genetic diseases, and the cumulative number of services has exceeded 10,000. The group has established branches in Beijing, Shanghai, Jiangsu and California in the United States. Its business covers 32 provinces and municipalities directly under the Central Government. It has successfully expanded to more than 20 countries including the United States, Britain, Russia, Japan, Thailand, Malaysia, and Cambodia, via establishing strategic cooperation and localized examination with New Hope, MFC, Genetix, Foundation Lab, CRHG and other well-known reproductive medicine centers. Dedicated to provide personalized reproductive genetics solutions together with global colleagues in the reproduction field for infertility patients, our efficient and convenient precise prenatal and preimplantation genetic testing technologies such as NICS non-invasive embryo screening, 9-hour rapid embryo chromosome detection, etc. are promoted to the world through technical output.
In the future, Yikon Genomics will continue to take "mastering extraordinary technology to achieve billions health" as mission, and provide high-quality medical testing services for the health of countless people and new births to contribute to the development of precision medicine.